Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
Status:
Recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety, and pharmacokinetics of Trastuzumab deruxtecan
(T-DXd) in participants with human epidermal growth factor 2 (HER2)-overexpressing locally
advanced, unresectable, or metastatic colorectal cancer (mCRC).